Principia Biopharma, Inc.. (PRNB) NASDAQ

$100.05 - (-)

Market Cap: $3.32B

As of 09/25/20 12:00 AM EDT. Market closed.

(PRNB)

Principia Biopharma, Inc.. (PRNB)
NASDAQ

$100.05
- (-)

Market Cap: $3.32B

As of 09/25/20 12:00 AM EDT. Market closed.

Add to Portfolio

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, ... read more

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. read less

COMPANY PROFILE
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martin Babler
Full Time Employees
103
CEO Compensation (Base)
$447,128
CEO Compensation (Total)
$2.32M
URL
Address
220 East Grand Avenue, CA, South San Francisco, 94080.
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Martin Babler
Full Time Employees
103
CEO Compensation (Base)
$447,128
CEO Compensation (Total)
$2.32M
Address
220 East Grand Avenue, CA, South San Francisco, 94080.
PRICE CHART FOR PRINCIPIA BIOPHARMA, INC.
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$100.05
Days Range
- - -
52 week range
$25.35 - $101.89
Volume
0
Avg. Volume (30 days)
2,469,813
Market Cap
$3.32B
Dividend Yield
-
P/E
-
Shares Outstanding
33,208,500
Open
-
Previous Close
$100.05
Days Range
- - -
52 week range
$25.35 - $101.89
Volume
0
Avg. Volume (30 days)
2,469,813
Market Cap
$3.32B
Dividend Yield
-
P/E
-
Shares Outstanding
33,208,500
FINANCIAL STATEMENTS FOR PRINCIPIA BIOPHARMA, INC.
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR PRINCIPIA BIOPHARMA, INC.
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
George SimeonDirectorSep 28, 2020 Option Exercise$100.002,982,855298,285,5000Sep 28, 2020, 05:27 PM
Becker Daniel J.DirectorSep 28, 2020 Option Exercise$100.00667,60066,760,0000Sep 28, 2020, 05:24 PM
Wolff StefaniChief Development OfficerSep 28, 2020 Option Exercise$100.0013,5921,359,2000Sep 28, 2020, 05:19 PM
Thomas DolcaChief Medical OfficerSep 28, 2020 Option Exercise$100.002,207220,7000Sep 28, 2020, 05:16 PM
Hardiman Roy C.Chief Business OfficerSep 28, 2020 Option Exercise$100.001,916191,6000Sep 28, 2020, 05:14 PM
Hardiman Roy C.Chief Business OfficerSep 28, 2020 Option Exercise$100.00117,76111,776,1000Sep 28, 2020, 05:14 PM
CHAI CHRISTOPHER YChief Financial OfficerSep 28, 2020 Option Exercise$100.003,302330,2000Sep 28, 2020, 05:11 PM
CHAI CHRISTOPHER YChief Financial OfficerSep 28, 2020 Option Exercise$100.003,799379,9000Sep 28, 2020, 05:11 PM
Goldstein David MChief Scientific OfficerSep 28, 2020 Option Exercise$100.0031,8263,182,6000Sep 28, 2020, 05:08 PM
Babler MartinPresident, CEOSep 28, 2020 Option Exercise$100.0057,5345,753,4000Sep 28, 2020, 05:07 PM
Babler MartinPresident, CEOSep 28, 2020 Option Exercise$100.001,023102,3000Sep 28, 2020, 05:07 PM
Hardiman Roy C.Chief Business OfficerSep 18, 2020 Option Exercise$5.865,00029,321122,761Sep 22, 2020, 08:02 PM
Hardiman Roy C.Chief Business OfficerSep 18, 2020 Sale$99.985,000499,917117,761Sep 22, 2020, 08:02 PM
Thomas DolcaChief Medical OfficerAug 18, 2020 Option Exercise$23.7715,000356,55016,826Aug 20, 2020, 08:17 PM
Thomas DolcaChief Medical OfficerAug 18, 2020 Sale$100.0015,0001,500,0001,826Aug 20, 2020, 08:17 PM
CHAI CHRISTOPHER YChief Financial OfficerAug 18, 2020 Option Exercise$3.007,50022,48311,039Aug 20, 2020, 08:01 PM
CHAI CHRISTOPHER YChief Financial OfficerAug 18, 2020 Sale$99.377,500745,2403,539Aug 20, 2020, 08:01 PM
Goldstein David MChief Scientific OfficerAug 10, 2020 Option Exercise$3.116,00018,63237,739Aug 12, 2020, 08:01 PM
Goldstein David MChief Scientific OfficerAug 10, 2020 Sale$88.616,000531,66536,881Aug 12, 2020, 08:01 PM
Thomas DolcaChief Medical OfficerJul 15, 2020 Option Exercise$23.7715,000356,55016,826Jul 17, 2020, 08:01 PM
Thomas DolcaChief Medical OfficerJul 15, 2020 Sale$80.0715,0001,201,0691,826Jul 17, 2020, 08:01 PM
Colowick AlanDirectorJul 01, 2020 Option Exercise$4.547,50034,0657,500Jul 02, 2020, 08:48 PM
Colowick AlanDirectorJul 01, 2020 Sale$60.007,500450,0000Jul 02, 2020, 08:48 PM
Babler MartinPresident, CEOJun 23, 2020 Option Exercise$3.0015,00044,96515,810Jun 25, 2020, 08:07 PM
Babler MartinPresident, CEOJun 23, 2020 Sale$61.8615,000927,88915,295Jun 25, 2020, 08:07 PM
Wolff StefaniChief Development OfficerJun 15, 2020 Sale$60.755,504334,38524,200Jun 17, 2020, 09:52 PM
Wolff StefaniChief Development OfficerMar 16, 2020 Sale$46.155,504254,03128,350Jun 17, 2020, 09:48 PM
Wolff StefaniChief Development OfficerDec 16, 2019 Sale$49.435,505272,09131,404Jun 17, 2020, 09:41 PM
Hardiman Roy C.Chief Business OfficerJun 12, 2020 Option Exercise$4.725,00023,618122,761Jun 15, 2020, 08:12 PM
Hardiman Roy C.Chief Business OfficerJun 12, 2020 Sale$61.165,000305,788121,166Jun 15, 2020, 08:12 PM
CHAI CHRISTOPHER YChief Financial OfficerMay 19, 2020 Option Exercise$3.005,67517,01211,039May 21, 2020, 08:01 PM
CHAI CHRISTOPHER YChief Financial OfficerMay 19, 2020 Sale$65.107,500488,2683,539May 21, 2020, 08:01 PM
Goldstein David MChief Scientific OfficerMay 07, 2020 Option Exercise$3.006,00017,98636,968May 08, 2020, 08:05 PM
Goldstein David MChief Scientific OfficerMay 07, 2020 Sale$60.166,000360,94133,687May 08, 2020, 08:05 PM
Colowick AlanDirectorMay 01, 2020 Option Exercise$4.548403,815840May 05, 2020, 08:07 PM
Colowick AlanDirectorMay 05, 2020 Option Exercise$4.546,66030,2506,660May 05, 2020, 08:07 PM
Colowick AlanDirectorMay 05, 2020 Sale$60.006,660399,6000May 05, 2020, 08:07 PM
Colowick AlanDirectorMay 01, 2020 Sale$60.0784050,4570May 05, 2020, 08:07 PM
Wolff StefaniChief Development OfficerMar 16, 2020 Option Exercise$4.545,50424,99941,113Mar 18, 2020, 05:08 PM
Wolff StefaniChief Development OfficerMar 16, 2020 Sale$46.155,504254,03139,359Mar 18, 2020, 05:08 PM
Hardiman Roy C.Chief Business OfficerMar 13, 2020 Option Exercise$4.725,00023,618121,903Mar 17, 2020, 05:08 PM
Hardiman Roy C.Chief Business OfficerMar 13, 2020 Sale$48.565,000242,816118,184Mar 17, 2020, 05:08 PM
Babler MartinPresident, CEOMar 03, 2020 Sale$63.4715,000952,08352,094Mar 05, 2020, 05:21 PM
CHAI CHRISTOPHER YChief Financial OfficerFeb 18, 2020 Option Exercise$3.002,5007,49412,266Feb 20, 2020, 05:02 PM
CHAI CHRISTOPHER YChief Financial OfficerFeb 18, 2020 Sale$65.897,500494,1869,582Feb 20, 2020, 05:02 PM
Goldstein DavidChief Scientific OfficerFeb 10, 2020 Option Exercise$3.006,00017,98636,968Feb 12, 2020, 07:03 PM
Goldstein DavidChief Scientific OfficerFeb 10, 2020 Sale$70.906,000425,40036,168Feb 12, 2020, 07:03 PM
Thomas DolcaChief Medical OfficerDec 19, 2019 Sale$60.0049529,700494Dec 20, 2019, 09:00 PM
Babler MartinPresident, CEODec 17, 2019 Sale$52.9625,0001,323,99673,339Dec 19, 2019, 09:06 PM
Babler MartinPresident, CEODec 18, 2019 Sale$53.664,500241,45919,196Dec 19, 2019, 09:06 PM
Wolff StefaniChief Development OfficerDec 16, 2019 Option Exercise$4.545,50525,00441,114Dec 18, 2019, 07:09 PM
Wolff StefaniChief Development OfficerDec 16, 2019 Sale$49.435,505272,09136,909Dec 18, 2019, 07:09 PM
Hardiman Roy C.Chief Business OfficerDec 13, 2019 Option Exercise$4.955,00024,743125,143Dec 13, 2019, 08:04 PM
Hardiman Roy C.Chief Business OfficerDec 13, 2019 Sale$49.415,000247,034121,762Dec 13, 2019, 08:04 PM
Becker Daniel J.DirectorNov 20, 2019 Buy$29.9455,0001,646,700667,600Nov 22, 2019, 08:07 PM
Goldstein DavidChief Scientific OfficerNov 07, 2019 Option Exercise$1.8810,00018,81539,819Nov 08, 2019, 09:01 PM
Goldstein DavidChief Scientific OfficerNov 07, 2019 Sale$32.3910,000323,91429,819Nov 08, 2019, 09:01 PM
Becker Daniel J.DirectorOct 29, 2019 Buy$33.989,196312,477612,600Oct 30, 2019, 04:16 PM
Becker Daniel J.DirectorOct 28, 2019 Buy$33.4168,4042,285,549603,404Oct 30, 2019, 04:16 PM
GLAXOSMITHKLINE PLCFormer 10% OwnerOct 18, 2019 Buy$28.00357,1429,999,9762,982,855Oct 22, 2019, 05:36 PM
George SimeonDirectorOct 18, 2019 Buy$28.00357,1429,999,9762,982,855Oct 22, 2019, 04:11 PM
Becker Daniel J.DirectorOct 18, 2019 Buy$28.00535,00014,980,000535,000Oct 22, 2019, 04:06 PM
New Leaf Ventures II, L.P.10% OwnerAug 13, 2019 Sale$35.00300,00010,500,0001,938,167Aug 15, 2019, 04:47 PM
ORBIMED ADVISORS LLC10% OwnerMay 21, 2019 Sale$30.251,000,00030,250,0001,605,713May 22, 2019, 12:43 PM
Sofinnova Venture Partners VIII, L.P.10% OwnerSep 18, 2018 Buy$17.00270,0004,590,0002,038,208Sep 20, 2018, 07:02 PM
ORBIMED ADVISORS LLC10% OwnerSep 18, 2018 Buy$17.00250,0004,250,0002,605,713Sep 20, 2018, 06:59 PM
Becker Daniel J.DirectorSep 18, 2018 Buy$17.00270,0004,590,000437,537Sep 20, 2018, 06:58 PM
New Leaf Ventures II, L.P.10% OwnerSep 18, 2018 Buy$17.00270,0004,590,000437,537Sep 20, 2018, 06:53 PM
George SimeonDirectorSep 18, 2018 Buy$17.00270,0004,590,0002,625,713Sep 20, 2018, 06:50 PM
GLAXOSMITHKLINE PLC10% OwnerSep 18, 2018 Buy$17.00270,0004,590,0002,625,713Sep 20, 2018, 05:18 PM
AKKARAJU SRINIVASDirectorSep 18, 2018 Buy$17.00175,0002,975,000383,480Sep 20, 2018, 04:14 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
George SimeonDirector09/28/2020298,285,500
Becker Daniel J.Director09/28/202066,760,000
Wolff StefaniChief Development Officer09/28/20201,359,200
Thomas DolcaChief Medical Officer09/28/2020220,700
Hardiman Roy C.Chief Business Officer09/28/2020191,600
Hardiman Roy C.Chief Business Officer09/28/202011,776,100
CHAI CHRISTOPHER YChief Financial Officer09/28/2020330,200
CHAI CHRISTOPHER YChief Financial Officer09/28/2020379,900
Goldstein David MChief Scientific Officer09/28/20203,182,600
Babler MartinPresident, CEO09/28/20205,753,400
Babler MartinPresident, CEO09/28/2020102,300
Hardiman Roy C.Chief Business Officer09/18/202029,321
Hardiman Roy C.Chief Business Officer09/18/2020499,917
Thomas DolcaChief Medical Officer08/18/2020356,550
Thomas DolcaChief Medical Officer08/18/20201,500,000
CHAI CHRISTOPHER YChief Financial Officer08/18/202022,483
CHAI CHRISTOPHER YChief Financial Officer08/18/2020745,240
Goldstein David MChief Scientific Officer08/10/202018,632
Goldstein David MChief Scientific Officer08/10/2020531,665
Thomas DolcaChief Medical Officer07/15/2020356,550
Thomas DolcaChief Medical Officer07/15/20201,201,069
Colowick AlanDirector07/01/202034,065
Colowick AlanDirector07/01/2020450,000
Babler MartinPresident, CEO06/23/202044,965
Babler MartinPresident, CEO06/23/2020927,889
Wolff StefaniChief Development Officer06/15/2020334,385
Wolff StefaniChief Development Officer03/16/2020254,031
Wolff StefaniChief Development Officer12/16/2019272,091
Hardiman Roy C.Chief Business Officer06/12/202023,618
Hardiman Roy C.Chief Business Officer06/12/2020305,788
CHAI CHRISTOPHER YChief Financial Officer05/19/202017,012
CHAI CHRISTOPHER YChief Financial Officer05/19/2020488,268
Goldstein David MChief Scientific Officer05/07/202017,986
Goldstein David MChief Scientific Officer05/07/2020360,941
Colowick AlanDirector05/01/20203,815
Colowick AlanDirector05/05/202030,250
Colowick AlanDirector05/05/2020399,600
Colowick AlanDirector05/01/202050,457
Wolff StefaniChief Development Officer03/16/202024,999
Wolff StefaniChief Development Officer03/16/2020254,031
Hardiman Roy C.Chief Business Officer03/13/202023,618
Hardiman Roy C.Chief Business Officer03/13/2020242,816
Babler MartinPresident, CEO03/03/2020952,083
CHAI CHRISTOPHER YChief Financial Officer02/18/20207,494
CHAI CHRISTOPHER YChief Financial Officer02/18/2020494,186
Goldstein DavidChief Scientific Officer02/10/202017,986
Goldstein DavidChief Scientific Officer02/10/2020425,400
Thomas DolcaChief Medical Officer12/19/201929,700
Babler MartinPresident, CEO12/17/20191,323,996
Babler MartinPresident, CEO12/18/2019241,459
Wolff StefaniChief Development Officer12/16/201925,004
Wolff StefaniChief Development Officer12/16/2019272,091
Hardiman Roy C.Chief Business Officer12/13/201924,743
Hardiman Roy C.Chief Business Officer12/13/2019247,034
Becker Daniel J.Director11/20/20191,646,700
Goldstein DavidChief Scientific Officer11/07/201918,815
Goldstein DavidChief Scientific Officer11/07/2019323,914
Becker Daniel J.Director10/29/2019312,477
Becker Daniel J.Director10/28/20192,285,549
GLAXOSMITHKLINE PLCFormer 10% Owner10/18/20199,999,976
George SimeonDirector10/18/20199,999,976
Becker Daniel J.Director10/18/201914,980,000
New Leaf Ventures II, L.P.10% Owner08/13/201910,500,000
ORBIMED ADVISORS LLC10% Owner05/21/201930,250,000
Sofinnova Venture Partners VIII, L.P.10% Owner09/18/20184,590,000
ORBIMED ADVISORS LLC10% Owner09/18/20184,250,000
Becker Daniel J.Director09/18/20184,590,000
New Leaf Ventures II, L.P.10% Owner09/18/20184,590,000
George SimeonDirector09/18/20184,590,000
GLAXOSMITHKLINE PLC10% Owner09/18/20184,590,000
AKKARAJU SRINIVASDirector09/18/20182,975,000
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR PRINCIPIA BIOPHARMA, INC.
LOADING...